Effect of Sharpunkha churna and Sharpunkhadi churna in the management of Yakrit Vikara

A Comparative Study to Evaluate the Efficacy of Sharpunkha churna and Sharpunkhadi churna in the management of Metabolic Dysfunction- Associated Fatty Liver Disease (~Yakrit Vikara) - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101430

Enrollment

Registered

2026-01-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient with NFS -1.455 or greater than -1.455. 2.Patient with positive clinical history of Metabolic Dysfunction- Associated Fatty Liver Disease Grade 1 and Grade 2. 3.Patient with classical symptoms suggesting of NAFLD/ Yakrit vikara that is Udarshool (pain in right upper quadrant/ epigastric region of the abdomen), Hrullas (feeling of nausea and vomiting), Arochak (loss of appetite), Klama (fatigue), Koshtha Dah (burning sensation in the abdomen). 4.Patient having age between 25 to 60 years with irrespective of gender. 5.Subject who are able to take medicine orally. 6.Subject who are willing to sign consent. 7.Patient with LFT showing raised ALT (Alanine transaminase level approximately more than 1.5 times the normal limit with/ without raised lipid profile and fasting blood glucose level within normal limit).

Exclusion criteria

Exclusion criteria: 1.Patient with history of alcohol intake. 2.Pregnant and lactating female. 3.Patient with positive markers of other liver diseases such as viral hepatitis, autoimmune hepatitis, Wilson s disease. 4.Subject with concomitant hepatotoxic and anti-dyslipedemic drugs.

Design outcomes

Primary

Measure	Time frame
Reduction in primary assessment criteria i.e NAFLD fibrosis score.Timepoint: 8 weeks and 4 days	—

Secondary

Measure	Time frame
Reduction in the level of- 1.SGPT 2.SGOT 3.AST/ ALT ratio 4.BMI 5.IFG 6.Sr. Triglyceride 7.S. Albumin Timepoint: 8 weeks & 4 days	—

Countries

India

Contacts

Public ContactProfDr Yogesh Kumar Pandey

Ch. Brahm Prakash Ayurved Charak Sansthan

dryogeshpandey@gmail.com9013858523

Outcome results